PX CHF2017 Seg04 Beta Blocker Role

(6:31)

PX CHF2017 Seg02 HFrEF Characteristics

(5:50)

PX CHF2017 Seg03 Measuring BNP levels

(5:23)

PX CHF2017 Seg07 Neprilysin inhibition

(8:9)

PX CHF2017 Seg01 Underappreciated Burden

(8:28)

Angiotensin Neprilysin Inhibition in Acute Descompensated Heart Failure

(15:11)

What Data Exist to Show Abuse-Deterrent Opioid Formulations Are Effective?

(1:11)

Heart Minute | BNP in Congestive \u0026 Hypertrophic Heart Failure

(3:7)

HFSA 2022: PROVE-HF: Effect of Sacubitril/Valsartan in HFrEF Pts With MR | Dr James L Januzzi

(7:42)

Characteristics of Patients with HFrEF

(5:50)

How Can Health-System Pharmacists Best Identify Potential Medication Errors?

(39)

Angiotensin Receptor Neprilysin Inhibition in Heart Failure

(8:9)

Challenges in Treating Patients with Hepatitis C

(1:16)

Sacubitril/Valsartan May Help Preserve Kidney Function in Patients With HFrEF

(3:19)

neprilysin inhibitors in heart failure and ckd eraedta 2018

(25:41)

Primary Care CAT- Entresto

(3:4)

PFPNmsfs2020PC21Matterhorn

(7:32)